Hypertension update and cardiovascular risk reduction in physically active individuals and athletes

Physician and Sportsmedicine

Volumn 38, Issue 1, 2010, Pages 11-20

  Oliveira, Leonardo P J ^a   Lawless, Christine E ^b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Sports Cardiology Consultants LLC   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Athletes; Exercise; Exercise performance; Hypertension

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CILAZAPRIL; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FELODIPINE; FOSINOPRIL; HYDROCHLOROTHIAZIDE; ISRADIPINE; LISINOPRIL; NITRENDIPINE; OXPRENOLOL; PERINDOPRIL; PLACEBO; PROPRANOLOL; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; UNINDEXED DRUG;

ANTIHYPERTENSIVE THERAPY; ATHLETE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFECT; EXERCISE; HEART FAILURE; HEART INFARCTION; HEART RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DYSFUNCTION; LIFESTYLE MODIFICATION; PHYSICAL ACTIVITY; PREVALENCE; REVIEW; RISK REDUCTION; SALT WASTING; SPORT; STROKE; UNSPECIFIED SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; ATHLETES; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; PHYSICAL ENDURANCE; RISK REDUCTION BEHAVIOR;

EID: 77950808405     PISSN: 00913847     EISSN: None     Source Type: Journal    
DOI: 10.3810/psm.2010.04.1757     Document Type: Review

References (64)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217- 223. (Pubitemid 40138015)
2. Lloyd-Jones D, Adams RJ, Brown TM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46-e215.
3. Lehmann M, Dürr H, Merkelbach H, Schmid A. Hypertension and sports activities: institutional experience. Clin Cardiol. 1990;13(3):197-208. (Pubitemid 20098777)
4. Hernelahti M, Kujala UM, Kaprio J, Karjalainen J, Sarna S. Hypertension in master endurance athletes. J Hypertens. 1998;16(11):1573-1577.
5. Ostchega Y, Yoon SS, Hughes J, Louis T. Hypertension awareness, treatment, and control-continued disparities in adults: United States, 2005-2006. Hyattsville, MD: National Center for Health Statistics; 2008. NCHS data brief.
6. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual BP to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-1913. (Pubitemid 35472129)
7. The 2008 Racial and Gender Report Card: College Sport. The Institute for Diversity and Ethics in Sport. http://www.tidesport.org/RGRC/2008/ 2008CollegRGRC.pdf. Accessed March 22, 2010.
8. Hanson P, Andrea BE. Treatment of hypertension in athletes. In: Delee J, Drez D, Stanitski CL, eds. Orthopaedic Sports Medicine: Principles and Practice. Philadelphia, PA: WB Saunders; 1994:307-319.
9. Pigozzi F, Rizzo M. Sudden death in competitive athletes. Clin Sports Med. 2008;27(1):153-181, ix.
10. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation. 2009;119(8):1085-1092.
11. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Hypertension. 2003;42(6):1206-1252.
12. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 suppl 4):555-576.
13. Warner, TD, Mitchell, JA. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet. 2008;371:270.
14. Sacks FM, Svetkey LP, Vollmer WM, et al; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344(1):3-10.
15. Pescatello LS, Franklin BA, Fagard R, Farquhar WB, Kelley GA, Ray CA; American College of Sports Medicine. American College of Sports Medicine position stand: exercise and hypertension. Med Sci Sports Exerc. 2004;36(3):533-553.
16. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev. 2009;(3):CD001841.
17. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23): 2981-2997.
18. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265(24):3255-3264.
19. World Anti-Doping Agency. The world anti-doping code: 2010 prohibited list. http://www.wada-ama.org/Documents/World-Anti-Doping-Program/WADP- Prohibited-list/WADA-Prohibited-List-2010-EN.pdf. Accessed January 21, 2010.
20. National Collegiate Athletic Association. 2009-10 NCAA banned drugs. http://www.ncaa.org/wps/wcm/connect/53e6f4804e0b8a129949f91ad6fc8b25/ 2009-10+Banned+Drug+Classes.pdf?MOD=AJPERES &CACHEID= 53e6f4804e0b8a129949f91ad6fc8b25. Accessed March 1, 2010.
21. National Collegiate Athletic Association. NCAA drug testing program 2009-10. http://www.ncaapublications.com/Uploads/PDF/Drug-Testing-Program-2009- 10df7a5fa6-0f13-41a4-adc3-8dad0b924de6.pdf. Accessed March 1, 2010.
22. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA. 1996;276(23):1886-1892.
23. Savage PJ, Pressel SL, Curb JD, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med. 1998;158(7):741-751.
24. Kjeldsen SE, Lyle PA, Kizer JR, et al; LIFE Study Group. The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy: the LIFE study. J Clin Hypertens (Greenwich). 2005;7(3):152-158.
25. Zakynthinos E, Pierrutsakos Ch, Daniil Z, Papadogiannis D. Losartan controlled blood pressure and reduced left ventricular hypertrophy but did not alter arrhythmias in hypertensive men with preserved systolic function. Angiology. 2005;56(4):439-449. (Pubitemid 41040530)
26. Chick TW, Halperin AK, Gacek EM. The effect of antihypertensive medications on exercise performance: a review. Med Sci Sports Exerc. 1988;20:447-454. (Pubitemid 18266126)
27. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805-2816.
28. Dahlöf B, Sever PS, Poulter NR, et al; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. (Pubitemid 41265663)
29. Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-2428.
30. Yusuf S, Teo KK, Pogue J, et al; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-1559.
31. Derman WE, Ernotte D, Noakes TD. Comparative effects of cilazapril and atenolol on maximal and prolonged submaximal exercise performance in hypertensive males. Am J Med. 1993;94(4A):69S-71S. (Pubitemid 23147409)
32. Gordon NF, Scott CB, Duncan JJ. Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men. Am J Cardiol. 1997;79(8):1065-1069.
33. Schmieder RE, Bähr M, Langewitz W, Rüddel H, Schächinger H, Schulte W. Efficacy of four antihypertensive drugs (clonidine, enalapril, nitrendipine, oxprenolol) on stress blood pressure. Am J Cardiol. 1989;63(18):1333-1338. (Pubitemid 19135036)
34. Stewart KJ, Effron MB, Valenti SA, Kelemen MH. Effects of diltiazem or propranolol during exercise training of hypertensive men. Med Sci Sports Exerc. 1990;22(2):171-177.
35. Szlachcic J, Hirsch AT, Tubau JF, Vollmer C, Henderson S, Massie BM. Diltiazem versus propranolol in essential hypertension: responses of rest and exercise blood pressure and effects on exercise capacity. Am J Cardiol. 1987;59(5):393-399. (Pubitemid 17032890)
36. Grossman E, Messerli FH, Oren S, Soria F, Schmieder RE. Disparate cardiovascular response to stress tests during isradipine and fosinopril therapy. Am J Cardiol. 1993;72(7):574-579. (Pubitemid 23259453)
37. Paterna S, Di Pasquale P, Parrinello G, et al. Comparison of the effects of felodipine and cilazapril on exercise performance in patients with mild to moderate hypertension: a crossover study. Drugs Exp Clin Res. 2000;26(4):125-131.
38. Enström I, Thulin T, Lindholm LH. Comparison between enalapril and lisinopril in mild-moderate hypertension: a comprehensive model for evaluation of drug efficacy. Blood Press. 1992;1(2):102-107.
39. De Rosa ML, Chiariello M. Candesartan improves maximal exercise capacity in hypertensives: results of a randomized placebo-controlled crossover trial. J Clin Hypertens (Greenwich). 2009;11(4):192-200.
40. Carreira MA, Tavares LR, Leite RF, et al. Exercise testing in hypertensive patients taking different angiotensin-converting enzyme inhibitors. Arq Bras Cardiol. 2003;80(2):133-137.
41. Yesilbursa D, Serdar A, Ilcol B, Türel B, Cordan J. Effects of fosinopril treatment on blood pressure during physical and mental stress test in essential hypertension. Blood Press. 1999;8(5-6):269-272. (Pubitemid 30220289)
42. Vanhees L, Defoor JG, Schepers D, et al. Effect of bisoprolol and atenolol on endurance exercise capacity in healthy men. J Hypertens. 2000;18(1):35-43. (Pubitemid 30093706)
43. Vanhees L, Fagard R, Lijnen P, Amery A. Effect of antihypertensive medication on endurance exercise capacity in hypertensive sportsmen. J Hypertens. 1991;9(11):1063-1068.
44. Mulvihill-Wilson J, Gaffney FA, Neal WW, Graham RM, Pettinger WA, Blomqvist CG. Single and combined therapy for systemic hypertension with propranolol, hydralazine and hydrochlorothiazide: hemodynamic and neuroendocrine mechanisms of action. Am J Cardiol. 1985;56(4): 315-320. (Pubitemid 15045239)
45. Nordrehaug JE, Vollset SE. Reduction of exercise-induced ventricular arrhythmias in mild symptomatic heart failure by benazepril. Am Heart J. 1993;125(3):771-776.
46. Bause GS, Fleg JL, Lakatta EG. Exercise-induced arrhythmias in diuretic-treated patients with uncomplicated systemic hypertension. Am J Cardiol. 1987;59(8):874-877.
47. Serro-Azul JB, de Paula RS, Gruppi C, et al. Effects of chlorthalidone and diltiazem on myocardial ischemia in elderly patients with hypertension and coronary artery disease. Arq Bras Cardiol. 2001;76(4):268-272. (Pubitemid 33709591)
48. Vescovo G, Dalla Libera L, Serafini F, et al. Improved exercise tolerance aft er losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition. Circulation. 1998;98(17):1742-1749. (Pubitemid 28492494)
49. Guazzi M, Palermo P, Pontone G, Susini F, Agostoni P. Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure. Am J Cardiol. 1999;84(9):1038-1043. (Pubitemid 29505372)
50. Kaplan NM, Gidding SS, Pickering TG, Wright JT Jr. Task Force 5: systemic hypertension. J Am Coll Cardiol. 2005;45(8):1346-1348.
51. Ting JH, Wallis DH. Medical management of the athlete: evaluation and treatment of important issues in sports medicine. Clin Podiatr Med Surg. 2007;24(2):127-158.
52. O'Connor FG, Meyering CD, Patel R, Oriscello RP; Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension, athletes, and the sports physician: implications of JNC VII, the Fourth Report, and the 36th Bethesda Conference Guidelines. Curr Sports Med Rep. 2007;6(2):80-84.
53. Almeida SS, Azevedo A, Castro A, et al. B-type natriuretic peptide is related to left ventricular mass in hypertensive patients but not in athletes. Cardiology. 2002;98(3):113-115. (Pubitemid 36158570)
54. Palmieri EA, Palmieri V, Innelli P, et al. Aerobic exercise performance correlates with post-ischemic flow-mediated dilation of the brachial artery in young healthy men. Eur J Appl Physiol. 2005;94(1-2):113-117. (Pubitemid 41174437)
55. Tzemos N, Lim PO, MacDonald TM. Exercise blood pressure and endothelial dysfunction in hypertension. Int J Clin Pract. 2009;63(2):202-206.
56. Thuillez C, Richard V. Targeting endothelial dysfunction in hypertensive subjects. J Hum Hypertens. 2005;19(suppl 1):21S-25S. (Pubitemid 40946031)
57. Joyner MJ, Green DJ. Exercise protects the cardiovascular system: effects beyond traditional risk factors. J Physiol. 2009;587(pt 23):5551-5558.
58. Belardinelli R, Capestro F, Misiani A, Scipione P, Georgiou D. Moderate exercise training improves functional capacity, quality of life, and endothelium-dependent vasodilation in chronic heart failure patients with implantable cardioverter defibrillators and cardiac resynchronization therapy. Eur J Cardiovasc Prev Rehabil. 2006;13(5):818-825. (Pubitemid 44454857)
59. Souza-Barbosa LA, Ferreira-Melo SE, Ubaid-Girioli S, Arantes Nogueira E, Yugar-Toledo JC, Moreno H Jr. Endothelial vascular function in hypertensive patients aft er renin-angiotensin system blockade. J Clin Hypertens (Greenwich). 2006;8(11):803-809.
60. Benndorf RA, Appel D, Maas R, Schwedhelm E, Wenzel UO, Böger RH. Telmisartan improves endothelial function in patients with essential hypertension. J Cardiovasc Pharmacol. 2007;50(4):367-371.
61. Tzemos N, Lim PO, MacDonald TM. Valsartan improves endothelial dysfunction in hypertension: a randomized, double-blind study. Cardiovasc Ther. 2009;27(3):151-158.
62. Koh KK, Quon MJ, Lee Y, et al. Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients. Eur Heart J. 2007;28(12):1440-1447. (Pubitemid 47343820)
63. Ghiadoni L, Magagna A, Versari D, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension. 2003;41(6):1281-1286. (Pubitemid 36706078)
64. Chung NA, Beevers DG, Lip G. Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension. Blood Press. 2004;13(3):183-189. (Pubitemid 38967763)